Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)

For parent study: Inclusion Criteria: * Male or female individuals between 16 to 65 years of age, with a diagnosis of Neurocysticercosis and 20 or less viable cysts. * Patients with a diagnosis of epilepsy secondary to Neurocysticercosis and a history of one or more spontaneous seizures within the previous year but not longer than 10 years. * Willingness to complete a minimum of two weeks of hospitalization. * If female of child bearing potential, negative urine pregnancy testing and willingness to use an adequate method of contraception while on study medications and for at least 3 months following Albendazole therapy. * Normal laboratory values for hematocrit, platelets, white blood cells and glucose and normal or decreased values for Alanine transaminase, Aspartate transaminase and creatinine. * Negative PPD measurement and if positive ( \> 9mm induration in the absence of other findings or immunosuppression ) , negative smears for TB. * Negative fecal exam for Taenia eggs or Strongyloides larvae. Exclusion Criteria: * Primary generalized seizures ( e.g., not caused by Neurocysticercosis ) * A history of generalized epileptic status . * A type of Neurocysticercosis which can expose the patient to increased risk during the study. * Patients with persistent or progressive symptomatic intracranial hypertension or intracranial hypertension. * Previous therapy with Albendazole or Praziquantel in the previous year. * Pulmonary tuberculosis, or symptoms compatible with tuberc…